Anti-tumor activity of arginine deiminase via arginine deprivation in retinoblastoma.
In spite of recent advances in the treatment of retinoblastoma, chemotherapy is still challenging in high-stage intraocular retinoblastoma or metastatic retinoblastoma. Here, we investigated whether arginine deprivation via arginine deiminase (ADI) could be a new anti-tumor therapy in retinoblastoma cells. Expression of argininosuccinate synthetase (ASS) was detected in human retinoblastoma tissues. Even with a high expression of ASS, ADI effectively inhibited the proliferation of retinoblastoma cells and induced retinoblastoma cell death in a dose-dependent manner. These results indicate that arginine deprivation via ADI could be another treatment option for retinoblastoma due to low ASS activity in retinoblastoma cells.
Kim
Jeong Hun
JH
Department of Ophthalmology, College of Medicine, Seoul National University, Seoul 110-744, Korea.
Kim
Jin Hyoung
JH
Yu
Young Suk
YS
Kim
Dong Hun
DH
Min
Bon-Hong
BH
Kim
Kyu-Won
KW
D000230:Adenocarcinoma; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001120:Arginine / Q000378:metabolism*; D001124:Argininosuccinate Synthase / Q000235:genetics / Q000378:metabolism; D001943:Breast Neoplasms; D002455:Cell Division; D045744:Cell Line, Tumor; D002470:Cell Survival; D015353:Eye Enucleation; D005134:Eye Neoplasms / Q000201:enzymology / Q000473:pathology / Q000601:surgery; D005260:Female; D006801:Humans; D006867:Hydrolases / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012175:Retinoblastoma / Q000201:enzymology / Q000473:pathology / Q000601:surgery
D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D001120:Arginine; D006867:Hydrolases; C019723:arginine deiminase; D001124:Argininosuccinate Synthase